Amplia Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

ASX:ATX Recent Insider Transactions by Companies or Individuals
Date	Value	Name	Entity	Shares	Max Price
25 Nov 24	BuyAU$1,274,818	Acorn Capital Limited	Company	11,330,840	AU$0.12
15 Nov 24	SellAU$413,845	Acorn Capital Limited	Company	3,522,893	AU$0.15
06 Nov 24	BuyAU$99,999	Allan Moss	Individual	869,562	AU$0.11
04 Nov 24	BuyAU$1,999,986	Platinum Investment Management Limited	Company	17,391,304	AU$0.11
09 Aug 24	SellAU$415,694	Platinum Investment Management Limited	Company	4,164,100	AU$0.14
06 Aug 24	SellAU$222,675	Pengana Capital Ltd.	Company	1,700,000	AU$0.13
19 Jun 24	BuyAU$45,500	Robert Peach	Individual	827,268	AU$0.055
15 May 24	BuyAU$296,392	Allan Moss	Individual	5,389,000	AU$0.055
15 May 24	BuyAU$44,560	Jane Bell	Individual	810,190	AU$0.055
15 May 24	BuyAU$33,917	Christopher Burns	Individual	616,672	AU$0.055
15 May 24	BuyAU$104,499	Robert Peach	Individual	1,900,005	AU$0.055
08 Apr 24	SellAU$74,322	Platinum Investment Management Limited	Company	911,770	AU$0.082

Insider Trading Volume

Insider Buying: ATX insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of ATX?
Owner Type	Number of Shares	Ownership Percentage
Public Companies	0	0%
Private Companies	12,369,184	3.57%
Hedge Funds	51,183,323	14.8%
Institutions	56,283,177	16.2%
Individual Insiders	58,006,898	16.7%
General Public	168,673,029	48.7%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 78.6%.

Top Shareholders

Top 23 shareholders own 51.32% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
14.8%	Platinum Investment Management Limited	51,183,323	AU$4.2m	44.8%	0.09%
7.96%	Acorn Capital Limited	27,583,089	AU$2.3m	174%	4.29%
5.69%	Allan Moss	19,731,062	AU$1.6m	4.61%	no data
4.39%	Pengana Capital Group Limited	15,200,044	AU$1.3m	0%	1.78%
3.9%	Pengana Capital Ltd.	13,500,044	AU$1.1m	-11.2%	1.45%
1.41%	Christian Behrenbruch	4,885,323	AU$405.5k	0%	no data
1.27%	Robert Peach	4,392,033	AU$364.5k	0%	no data
1.14%	Ctx Crc Ltd	3,940,579	AU$327.1k	0%	no data
1.07%	Christopher Burns	3,720,791	AU$308.8k	0%	no data
1.06%	Warwick Tong	3,677,354	AU$305.2k	21.9%	no data
0.9%	Heh Entreprises Pty Ltd	3,102,500	AU$257.5k	0%	no data
0.82%	Jane Bell	2,835,664	AU$235.4k	-29.3%	no data
0.81%	Anthony Martin	2,820,323	AU$234.1k	0%	no data
0.78%	J&J Stuart Pty Ltd	2,700,000	AU$224.1k	0%	no data
0.76%	Ravinna Pty Ltd	2,626,105	AU$218.0k	0%	no data
0.7%	Sharon Lewis	2,430,000	AU$201.7k	0%	no data
0.7%	Robert Greenslade	2,412,500	AU$200.2k	0%	no data
0.64%	Nicholas McDonald	2,216,673	AU$184.0k	0%	no data
0.64%	Mark Devlin	2,215,237	AU$183.9k	0%	no data
0.56%	Andrew Podolak	1,925,000	AU$159.8k	0%	no data
0.48%	Mark Sullivan	1,661,428	AU$137.9k	0%	no data
0.44%	Michael Whiting	1,541,755	AU$128.0k	0%	no data
0.44%	Tracey Whiting	1,541,755	AU$128.0k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/22 20:10
End of Day Share Price	2024/12/20 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amplia Therapeutics Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution